Murray Resnick Professor of Pathology and Laboratory Medicine

Expertise/Certifications: Surgical Pathology, Gastrointestinal (GI) Pathology, Anatomic Pathology, Molecular Diagnostics
Office number: 444-5169
(Lab Customer Service: 401-793-4242)

Dr. Murray Resnick is Director of Surgical Pathology and Director of GI Pathology at Lifespan/Rhode Island Hospital, Co-Director of the Molecular Pathology Core Facility of the COBRE Center for Cancer Research Development at Lifespan, and is Professor of Pathology and Laboratory Medicine at Brown University School of Medicine. He came to Rhode Island in 2002 upon relocating from Israel where he worked as Director of the Department of Pathology at Carmel Medical Center in Haifa. Dr. Resnick received his M.D. and Ph.D. degrees from Hadassah Medical School, Hebrew University, in Jerusalem. He completed his residency in pathology and GI pathology fellowship training at the Brigham and Women's Hospital in Boston. His research subspeciality is in the area of GI pathology.

Brown Affiliations

Research Areas

scholarly work

 Lu S, Mukkada VA, Mangray S, Cleveland K, Shillingford N, et al (2012) MicroRNA profiling in mucosal biopsies of eosinophilic     esophagitis patients pre and post glucocorticoid steroid treatment and relationship with mRNA target expression. PLoS One 7:e40676

Cao W, Tian W, Hong J, Li D, Tavares R, et al (2013) Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Phys Gast and Liver 304:G322-27.

Lu S, Singh K, Magray S, Tavares R, Nobel L, et al (2013) Claudin expression in high grade invasive ductal carcinoma of the breast. Mod Pathol 26:485-95.

Matoso A, Mukkada V, Lu S Monahan R, Cleveland K, Noble L, Mangray S, Resnick MB. (2013) Expression microarray analysis identifies novel epithelial derived proteins in eosinophilic esophagitis. Mod Pathol  26:665-672.

Taliano RJ, Lu S, Singh K, Mangray S, Tavares R, Nobel L, et al (2013) Calretinin expression in high grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis. Human Pathology 44:2743-50.

Matoso A, Allen D, Herzlinger M, Ferreira J, Chen S, Lu S, et al (2014) Correlation of ALOX15 expression with eosinophilic or reflux esophagitis in a cohort of pediatric patients with esophageal eosinophilia. Human Pathology (accepted for publication).

Sargent DJ, Shi Q, Gill S, Louvet C, Everson RB, Kellner U, et al (2014) Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study. Clin Can Res (accepted for publication).


research overview

1) Analysis of novel diagnostic and prognostic markers in gastrointestinal malignancies using molecular techniques;
2) Identification of novel proteins involved in  the pathogenesis of Eosinophilic Esophagitis and other non-neoplastic GI disorders;
3) Computerized morphometry in experimental pathology.

funded research


COBRE Center for Cancer Research Development  

#5 P20 GM103421 Molecular Pathology CoreNational Institutes of Health/National Institute of General Medical Sciences  09/30/02 – 04/30/14 NCE            Role:  Co-Investigator


 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2 Overexpressing Esophageal Adenocarcinoma                   

#RTOG-1010 National Institutes of Health NCI CTROC BIQSFP Radiation Therapy Oncology Group


Role:  Co-Principal Investigator


Single Agent Adjuvant Aflibercept for Patients with Resected or Ablated Metastatic Colorectal Cancer:  A Randomized Phase II Study         #BrUOG-261 SANOFI


Role:  Co-Investigator